Loading…
NervGen Pharma Corp. is projected to rise to $2.04 by 2027, a +10% move from its current price of $1.86. NGEN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $1.79 | $1.86 | $1.93 | +0.04% |
| Jul 13 | $1.77 | $1.86 | $1.96 | +0.08% |
| Jul 14 | $1.75 | $1.86 | $1.99 | +0.11% |
| Jul 15 | $1.73 | $1.86 | $2.01 | +0.15% |
| Jul 16 | $1.72 | $1.86 | $2.02 | +0.19% |
| Jul 17 | $1.70 | $1.86 | $2.04 | +0.23% |
| Jul 18 | $1.69 | $1.86 | $2.06 | +0.27% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.69 | $1.86 | $2.06 | +0.27% |
| Week 2 | $1.63 | $1.87 | $2.15 | +0.53% |
| Week 3 | $1.58 | $1.87 | $2.22 | +0.80% |
| Week 4 | $1.55 | $1.88 | $2.29 | +1.07% |
| Week 5 | $1.51 | $1.88 | $2.35 | +1.34% |
| Week 6 | $1.49 | $1.89 | $2.40 | +1.61% |
| Week 7 | $1.46 | $1.89 | $2.46 | +1.88% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease.
The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study.
NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
NervGen Pharma, symbol NGEN, is currently priced at $1.85.
Its market capitalization is $213.89M and it ranks 5539.
The long-range forecast envisions upside potential, with 2026 avg $1.85 and 2050 avg $10.50, and a 2050 max of $22.60.
Additional milestones evident in the forecast show year-by-year progress, including higher max prices by 2035 ($7.99) and 2040 ($10.38), reflecting growing upside.
A major floor 21.1% below — a decisive break under it would weaken the trend.
The nearest floor, 7.0% below — buyers have tended to step in here.
The nearest ceiling, 18.3% above — a clean break opens room to run.
A major ceiling 136.0% above — clearing it would confirm fresh momentum.
Key NGEN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NGEN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.94 | Sell | $1.92 | Sell |
| MA 10 | $1.98 | Sell | $1.96 | Sell |
| MA 20 | $2.00 | Sell | $2.04 | Sell |
| MA 50 | $2.57 | Sell | $2.49 | Sell |
| MA 100 | $3.30 | Sell | $2.99 | Sell |
| MA 200 | $3.55 | Sell | $3.20 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 37.70 | Neutral |
| Stoch RSI (14) | 32.17 | Neutral |
| CCI (20) | -79.40 | Neutral |
| Williams %R (14) | -89.66 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | -8.74 | Sell |
| Bollinger %B (20,2) | 0.24 | Neutral |
| Stochastic %K (14) | 10.34 | Buy |
| TRIX (15) | -1.14 | Sell |
| Awesome (5,34) | -0.09 | Sell |
| Ultimate (7,14,28) | 29.88 | Buy |
| Momentum (10) | -0.03 | Sell |
| Aroon Osc (25) | 24.00 | Buy |
| Hull MA (9) | 1.84 | Buy |
| ADX (14) | 25.80 | Sell |
| ATR (14) | 0.08 | Info |
The 14-day RSI is 40, with sentiment NEUTRAL.
The 50-day simple moving average is $2.65 and the 200-day simple moving average is $3.56, with the current price of $1.85 below both.
The 30-day price range spans $1.43 to $2.40, with support at $1.73 and resistance at $2.20.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.73 | $1.86 | $2.55 | 0% | Neutral | |
| $1.57 | $2.04 | $2.83 | +10% | Neutral | |
| $1.91 | $2.59 | $3.77 | +39% | Bullish | |
| $2.18 | $3.04 | $4.60 | +63% | Bullish | |
| $2.31 | $3.33 | $5.19 | +79% | Bullish | |
| $2.19 | $3.23 | $5.18 | +74% | Bullish | |
| $1.99 | $3.02 | $4.95 | +62% | Bullish | |
| $2.31 | $3.58 | $6.01 | +93% | Bullish | |
| $2.59 | $4.12 | $7.04 | +121% | Bullish | |
| $2.85 | $4.63 | $8.06 | +149% | Bullish | |
| $3.16 | $5.68 | $10.67 | +205% | Bullish | |
| $5.07 | $10.99 | $23.02 | +491% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.73 | $1.86 | $2.19 | +0.00% |
| August 2026 | $1.52 | $1.81 | $2.22 | -2.83% |
| September 2026 | $1.60 | $1.93 | $2.41 | +6.54% |
| October 2026 | $1.64 | $1.99 | $2.51 | +3.15% |
| November 2026 | $1.59 | $1.94 | $2.48 | -2.30% |
| December 2026 | $1.60 | $1.97 | $2.55 | +1.65% |
Click any year to see its month-by-month NGEN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The NGEN price prediction for 2026 points to an average of $1.86 (low $1.73, high $2.55) — a potential gain of 0% on today's $1.86. A consolidation phase looks the most probable path here.
In 2027, NGEN is projected to trade between $1.57 and $2.83, averaging $2.04 — a potential gain of +10% from today's $1.86. That is up +10% on the projected 2026 average. Price action looks broadly range-bound.
NervGen Pharma Corp.'s 2028 outlook centres on $2.59, within a $1.91 to $3.77 range. That is up +27% on the projected 2027 average. That marks a +39% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, NGEN could reach as high as $4.60, with a base case around $3.04 and support toward $2.18 — roughly +63% from $1.86. Momentum favours further upside here.
Expect NGEN to range from $2.31 to $5.19 through 2030. The $3.33 average target implies a +79% move from current prices. That is up +9% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The NGEN price prediction for 2031 points to an average of $3.23 (low $2.19, high $5.18) — a potential gain of +74% on today's $1.86. Momentum favours further upside here.
In 2032, NGEN is projected to trade between $1.99 and $4.95, averaging $3.02 — a potential gain of +62% from today's $1.86. That is -7% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
NervGen Pharma Corp.'s 2033 outlook centres on $3.58, within a $2.31 to $6.01 range. That is up +19% on the projected 2032 average. That marks a +93% change versus current levels. Momentum favours further upside here.
By 2034, NGEN could reach as high as $7.04, with a base case around $4.12 and support toward $2.59 — roughly +121% from $1.86. Buyers look set to stay in control over this stretch.
Expect NGEN to range from $2.85 to $8.06 through 2035. The $4.63 average target implies a +149% move from current prices. That is up +12% on the projected 2034 average. Momentum favours further upside here.
The NGEN price prediction for 2040 points to an average of $5.68 (low $3.16, high $10.67) — a potential gain of +205% on today's $1.86. Buyers look set to stay in control over this stretch.
In 2050, NGEN is projected to trade between $5.07 and $23.02, averaging $10.99 — a potential gain of +491% from today's $1.86. That is up +94% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in NGEN today (≈ 537.634409 NGEN) could be worth
$5,909.95
+$4,909.95 (+491%) by 2050 · US Dollar
Based on the average projected NGEN price of $10.99 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NGENwould be worth at today's price.
$1,000 invested in NGEN on Jul 10, 2025 (≈ 340.367601 NGEN) would be worth
$633.08
-$366.92 (-36.7%) today · 0.63× · US Dollar
Based on a NGEN entry price of $2.94 vs. today's $1.86.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.12 | $877.36 | -12.3% |
| 1 month ago | $1.73 | $1,075.14 | +7.5% |
| 3 months ago | $4.05 | $459.26 | -54.1% |
| 6 months ago | $5.65 | $329.2 | -67.1% |
| 1 year ago | $2.94 | $633.08 | -36.7% |
| All time (5.0y) ago | $1.31 | $1,419.85 | +42.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NGEN forecast.
Our base-case forecast reaches $3.70 around 2034.
Implied market cap at $3.70: $393.73M
From 2026 to 2027, the forecast shows a path from avg $1.85 to $2.00, with ROI 0% in 2026 and 7.9% in 2027; sentiment remains NEUTRAL.
From 2028 onward, sentiment is BULLISH, with 2028 avg $2.54, max $3.75, min $1.86, ROI 37.4%; 2029 avg $3.01, max $4.62, min $2.13, ROI 62.9%.
By 2030 the forecast shows avg $3.28, max $5.19, min $2.24, ROI 77.2%; by 2035 avg $4.49, max $7.99, min $2.70, ROI 142.9%.
In the later horizon, 2040 shows avg $5.40, max $10.38, min $2.89, ROI 191.7%; 2050 shows avg $10.50, max $22.60, min $4.73, ROI 467.6%.
Overall, the forecast depicts a bullish path with substantial upside, but these are estimates and not guarantees.
Tap a question to reveal the answer.
Avg price $3.28, min $2.24, max $5.19; ROI 77.2%; sentiment BULLISH.
Forecasts show bullish sentiment from 2028 onward and potential upside, with 2050 avg $10.50 and ROI 467.6%; but these are estimates, not guarantees.
The forecast max by 2035 is $7.99; by 2040 max $10.38; by 2050 max $22.60.
Current price $1.85.
Market capitalization $213.89M.
NervGen Pharma Corp. Community Discussion
0Share your NervGen Pharma Corp. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.